These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12243078)

  • 21. [Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
    Nagayoshi J; Higashi T; Maruyama Y
    Hinyokika Kiyo; 1999 Aug; 45(8):543-6. PubMed ID: 10500960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
    Alexander A; Crook J; Jones S; Malone S; Bowen J; Truong P; Pai H; Ludgate C
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):23-30. PubMed ID: 19395187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of carcinoma of the prostate to withdrawal of flutamide.
    Collinson MP; Daniel F; Tyrrell CJ; Teasdale C
    Br J Urol; 1993 Nov; 72(5 Pt 1):662-3. PubMed ID: 10071562
    [No Abstract]   [Full Text] [Related]  

  • 32. [Multiple myeloma diagnosed during hormonal therapy for prostate cancer: report of two cases].
    Yoshinaga A; Okada Y; Ichiyanagi N; Kamata S
    Hinyokika Kiyo; 2012 May; 58(5):243-7. PubMed ID: 22767278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N; Hasegawa Y
    Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
    Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
    BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 37. [A case of prostate cancer with multiple pulmonary metastases].
    Katoh H; Yamamoto N; Harada Y; Chang PK; Takeuchi T; Kanematsu M; Kuriyama M; Ban Y; Matsui E
    Hinyokika Kiyo; 1987 Mar; 33(3):441-6. PubMed ID: 3618415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
    Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
    BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer.
    Yamamoto S; Yonese J; Kawakami S; Tsukamoto T; Ohkubo Y; Tatokoro M; Fukui I
    Int J Clin Oncol; 2006 Aug; 11(4):326-8. PubMed ID: 16937308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.